Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

A study on how  generic competition can rapidly lower the prices of drugs with high hepatitis C cure rates, like sofosbuvir and daclatasvir and help achieve global treatment scale-up, 12th January, 2016

Click here for more details.

/ News

infirmly Share the Post

http://cooperativates.it/1751-dtit37538-incontri-pavona.html Related Posts

Flawed patents on hepatitis C drugs latest to be challenged in global push for access
Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Progress report on access to hepatitis C treatment, WHO March 2018
Letter from Asian community and treatment advocates to Chief Executive Officer of CHAI regarding the Quick start program and concerns that patients would have to pay for sofosbuvir and diagnostics to be a part of the program in October 2016
Updated Patent Situation on Key Products for Hepatitis C Treatment in Asia – August 2015
Availability and Pricing of Generic Sofosbuvir in India – Updated 10 September 2015
Asia Pacific Situational Updates on Generic DAAs – June 2017